Recent Articles from Investor Brand Network

Oncotelic Therapeutics (OTCQB: OTLC), 45% owner of the Sapu Nano joint venture, announced new pharmacokinetic and tissue-distribution data showing that Sapu003, its intravenous Deciparticle (TM) formulation of everolimus, dramatically reduces gastrointestinal drug accumulation compared with oral everolimus. Oral dosing drives extreme gut exposure—up to 2,448× plasma levels in the stomach—while IV Sapu003 limits GI tissue levels to just 36–48× plasma, representing reductions of up to 67-fold. The company stated that this shift may improve tolerability, maintain the drug’s intrinsic metabolic profile, and provide more consistent systemic exposure.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with highlights from a recent webinar. The study in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints for safety and tolerability and established a clear recommended Phase 2 dose. Encouraging signals of durable disease control were observed, particularly in tumors with DNA damage repair pathway deficiencies. Building on these results, Lantern is advancing multiple biomarker-guided Phase 1b/2 trials across triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma. The company and independent analysts estimate LP-184’s aggregate market opportunity could exceed $10 billion annually.

A2Z Cust2Mate Solutions (NASDAQ: AZ), a global smart retail technology company, said it entered an agreement with a premium grocery retailer operating more than 50 stores in Central America to deploy the A2Z Cust2mate smart cart platform. Initial rollout is planned for early 2026 in two flagship locations, with the shared goal of expanding to a full chain-wide deployment following successful implementation. The Company said the agreement marks a significant milestone for large-scale smart cart adoption in Central America, supported by its regional channel partner Trixo, and will help redefine the in-store experience, enhance retail media opportunities, and generate new data insights. CEO Gadi Graus said the collaboration represents a major leap for smart retail in the region and sets the stage for scalable adoption across the entire chain.

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements.

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) and may include paid advertising.

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising.

Micropolis AI Robotics (NYSE American: MCRP), a UAE-based developer of autonomous mobile robots and AI-driven security solutions, said it signed a non-binding Letter of Intent with QSS Robotics to establish a strategic collaboration for the distribution, localization, and deployment of Micropolis technologies across Saudi Arabia. The LOI outlines plans for commercial representation, joint engagement with government and private-sector customers, and integration and after-sales support under Micropolis supervision, building on agreements between the companies dating to 2022. Micropolis will provide its full suite of technologies, including M01 and M02 autonomous mobility platforms, Mission Planner and HD Mapping systems, Tele-Operator tools, and Microspot AI modules. QSS Robotics will act as Micropolis’ commercial and technical partner in the Kingdom. CEO Fareed Aljawhari said the agreement expands the Company’s reach in Saudi Arabia and reflects the strong alignment between the two companies.

Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,” which examines the growing burden of rare diseases affecting more than 30 million Americans and the urgent need for new therapies. The article spotlights Soligenix’s late-stage development of HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma, now in its final confirmatory study before worldwide marketing submissions, and places the Company’s efforts at the intersection of advancing treatment options and emerging national health policy initiatives.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, said it will present at the 2025 Annual Meeting of the Parkinson Study Group, held Dec. 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson’s biomarker results showing that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap, which also reduces tau biomarkers linked to disease progression. Annovis will also debut a cross-study comparison of all completed trials, offering the most comprehensive view to date of cognitive outcomes across indications and underscoring that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the Company’s strategic path forward.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”) formed a new business unit dedicated to driving the adoption of its quantum computing products and services within the U.S. government. Led by seasoned government and public sector business executive Jack Sears Jr., the newly established unit will support D-Wave’s enterprise-wide U.S. government-related initiative.

This article has been disseminated on behalf of Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) and may include paid advertising.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug filing for NRX-101 to include use of the drug in combination with Transcranial Magnetic Stimulation for depression, including suicidal depression. The update follows evidence suggesting NRX-101 may significantly enhance TMS outcomes, with published studies showing more than two-fold improvements in symptom reduction and clinical response rates exceeding 80%. The Company noted NRX-101’s D-cycloserine component appears to augment neuroplasticity associated with TMS, while its low-dose lurasidone is intended to mitigate D-cycloserine’s known risk of low-grade hallucinations. NRx said it aims to validate the findings in a well-controlled trial of about 120 participants and is in partnership discussions with TMS device manufacturers to pursue joint registration studies and potential label augmentation.

Newton Golf Company (NASDAQ: NWTG), a leader in physics-based golf shaft technology, said it achieved the highest single-day sales total in its history on Black Friday, driven by demand for its Fast Motion and Motion shaft families, and confirmed that November 2025 marks its strongest November on record. The Company reported its largest-ever 24-hour volume of direct-to-consumer orders, supported by rising tour adoption, greater brand visibility, strong repeat customer engagement, and a surge of first-time buyers. CEO Greg Campbell said the results reflect growing enthusiasm for Newton’s technology, noting Fast Motion remains its most successful product launch to date.

China’s battery-car mastery is propelling its flying vehicle manufacturers ahead of global rivals. Expertise developed through years of electric vehicle production and unmanned aircraft development is giving domestic companies a distinct edge in the nascent aerial mobility market.

Quantum technology is moving from distant theory to something businesses and the public are starting to pay attention to. A new study called the Quantum Index Report 2025 shows how interest in quantum computing is growing, even though many people still do not fully understand it.

BYD, a Chinese electric vehicle maker, is looking to leverage its Blade Battery as a way to reduce the quantity of minerals needed during the manufacture of batteries for EVs. Its battery technology is specifically designed to reduce the amount of nickel and cobalt required in vehicle electrification, and in this way, boost sustainability efforts as the world transitions to greener forms of transport.

This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement.

A judge on the Michigan Court of Claims is set to review arguments over whether state lawmakers crossed a constitutional line when they approved a new tax on cannabis. The hearing centers on a 24% levy on wholesale cannabis transactions that became a key part of the state budget signed by Governor Gretchen Whitmer last month.

Disseminated on behalf of Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) and may include paid advertising.

Massimo Group (NASDAQ: MAMO) said its Board approved adding Bitcoin as part of a long-term treasury reserve strategy, with initial purchases already begun and holdings to be disclosed in upcoming SEC filings or via Form 8-K. The Company said the program will be funded primarily through operating cash flows, with the option to use market instruments, and will employ institutional-grade custody with multi-signature cold storage and audit-ready controls. Massimo expects Bitcoin to represent a single-digit percentage of total assets over five years, positioning it as a strategic reserve rather than an operating asset. CEO David Shan said the move reflects a long-term view on liquidity diversification, inflation resilience and the maturation of digital asset infrastructure.

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

HealthLynked (OTCQB: HLYK), an AI-driven global healthcare network focused on improving care coordination and reducing costs, appointed Chris G. Pulos of Marsh McLennan Agency and Jason Bishara of NSI Insurance Group to its Board. The Company said the additions bring decades of experience in employer benefits, payer strategy, insurance and risk management as HealthLynked expands collaborations with insurers, employer groups and healthcare organizations. Founder and CEO Dr. Michael Dent said their expertise will support national scaling of the HealthLynked Network and its AI platform, ARI, while strengthening governance ahead of a planned Nasdaq Capital Market listing.

OptimumBank Holdings (NYSE American: OPHC), a bank holding company that owns 100% of community bank OptimumBank, headquartered in Fort Lauderdale, Florida, reported another period of higher earnings, loan expansion, and deposit growth in the third quarter of 2025. The bank posted net income of $4.32 million, or $0.37 per basic share, according to its latest update ( https://ibn.fm/6jUHu ).

GlobalTech (OTC: GLTK), a U.S.-based technology holding company focused on AI, big data and emerging technologies, said it entered a definitive agreement to acquire a 51% interest in 123 Investments Limited d/b/a Moda in Pelle, a premium UK footwear brand with approximately $37 million in net revenue last year. The Company said the deal is expected to add a new revenue stream, strengthen its UK operational presence and enhance e-commerce capabilities through Thrivo AI integration, with closing expected within 30 days subject to customary conditions. CEO Dan Green said the acquisition aligns with GlobalTech’s value-creation strategy and will support technology deployment across both businesses. GlobalTech said the 51% stake will be purchased through a combination of common stock and Convertible Series A Preferred Stock, which convert to common stock upon a Nasdaq Capital Market uplisting or other specified conditions and carry no dividends.

HealthLynked (OTCQB: HLYK), an AI-driven global healthcare network focused on improving care coordination and reducing costs, appointed Chris G. Pulos of Marsh McLennan Agency and Jason Bishara of NSI Insurance Group to its Board. The Company said the additions bring decades of experience in employer benefits, payer strategy, insurance and risk management as HealthLynked expands collaborations with insurers, employer groups and healthcare organizations. Founder and CEO Dr. Michael Dent said their expertise will support national scaling of the HealthLynked Network and its AI platform, ARI, while strengthening governance ahead of a planned Nasdaq Capital Market listing.

Oncotelic Therapeutics (OTCQB: OTLC) said its 45%-owned joint venture, Sapu Nano, reported new data at the 2025 San Antonio Breast Cancer Symposium showing that its Deciparticle(TM) nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides—into sub-20 nm nanoparticles suitable for IV delivery. The Company said the findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities that support rapid translation to Phase 1 supply. CEO Dr. Vuong Trieu said the results position Deciparticle as a modular engine for multiple oncology, immunology and peptide drug candidates, with Sapu003 representing the first of a broader pipeline.

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated New Drug Application for KETAFREE(TM), a preservative-free intravenous ketamine formulation, deeming the submission “substantially complete” and assigning a July 29, 2026 review goal date. CEO Jonathan Javitt said KETAFREE is designed to provide a single-patient, preservative-free alternative to current multidose ketamine vials that contain Benzethonium Chloride, a compound no longer recognized as safe by the FDA. The Company said KETAFREE aligns with MAHA initiatives to remove toxic substances from medicines and supports domestic supply-chain priorities, with potential 2026 approved drug sales if approved on schedule. NRx noted the program is separate from NRX-100, its Fast Track-designated treatment for suicidal depression, and said it continues to advance its broader pipeline and HOPE Therapeutics clinics.

Stewards (OTC: SWRD), a diversified financial company operating across private credit, real assets and digital finance, appointed Scott McGowan as chief marketing officer to lead integrated marketing and communications as the Company expands its operating segments and advances toward a planned Nasdaq Capital Market uplisting. McGowan, formerly director of investor relations at InvestorBrandNetwork and previously CEO of a strategic communications consultancy, brings more than 20 years of experience advising growth-stage companies on brand positioning, capital-markets strategy and stakeholder engagement. President Shaun Quin said McGowan will strengthen transparency and unify messaging as Stewards enters its next phase of growth.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it will host a corporate update conference call on Dec. 2, 2025, at 9 a.m. Eastern to review recent clinical, regulatory and operational developments.

European auto sales grew 4.9% in October as electric models outpaced gas and diesel counterparts for the first time. Data from the European Automobile Manufacturers’ Association (ACEA) captures a pivotal moment for an industry that has weathered multiple challenges throughout the year, from trade tensions to slower-than-expected technological transitions. According to the ACEA, registrations across the EU, Britain and EFTA countries reached 1.092 million units in October.

Last week saw the price of copper drop slightly, pressured by increasing expectations of a reduction in interest rates by the Federal Reserve and a firmer dollar. On the London Metal Exchange, three-month copper hit $10,780.50 per metric ton, representing a 0.2% increase.

The steep cost of healthcare in the U.S. has always been, and is becoming an even bigger political issue with each passing year. The issue was at the center of the recent shutdown of the federal government and the shutdown was only ended after a promise that the expiring healthcare subsidies would be voted on this month. Health insurance costs are soaring while citizens grapple with a high cost of living.

A new McKinsey Global Institute report offers a counterpoint to the widespread worry that AI will wipe out large segments of the workforce. While the research acknowledges that current tools could theoretically handle approximately 57% of tasks, the authors say this figure reflects what is technically possible, not what companies are likely to implement in practice.

Microsoft has secured renewable electricity supply from two Spanish solar facilities through an agreement with Madrid-based developer Zelestra . The power purchase arrangement includes funding for community sustainability programs through nonprofit organization ECODES, linking clean energy procurement with local social impact initiatives in a model that’s increasingly being adopted by technology companies.

Japan is moving to tighten safeguards in its digital asset industry by preparing rules that would force crypto exchanges to maintain reserves for potential customer losses.

YouTube is bringing back private messaging inside its mobile app, six years after removing the feature. The company has started testing a new video-sharing and chat tool for users aged 18 and above in Ireland and Poland. This test allows people to share long videos, Shorts, and live streams directly within the YouTube app, making it easier to discuss content without switching to other apps like WhatsApp or Instagram.

BioMedWire Editorial Coverage : Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis. This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc. (NASDAQ: SNGX) ( Profile ), a late-stage biopharmaceutical company, is developing multiple treatments for rare diseases, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma, and is now conducting the final confirmatory clinical study required before filing for worldwide marketing approval. As the Trump administration advances new health policy initiatives affecting chronic and rare diseases, Soligenix’s work sits at a critical intersection of medical innovation and national health priorities. The company is working alongside several leading companies committed to making an impact in the pharmaceutical and life sciences space, including Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY) and…

Cannabis retailers across the U.S. are adjusting to an unexpected shift in shopper behavior as the youngest legal buyers reshape the market. Gen Z customers are coming into stores, but they are approaching cannabis with more intention, more research, and more caution than many of the shoppers who came before them.

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) a nd may include paid advertising.

Across South Asia, connectivity remains fragmented. While mobile penetration has surged, fixed broadband adoption lags, leaving millions without access to the high-speed infrastructure necessary for modern enterprise operations, e-commerce, and digital financial services. Yet this gap represents opportunity: companies that can combine traditional telecom infrastructure with emerging technologies stand to capture exponential value as digital adoption accelerates.

Disseminated on behalf of SPARC AI Inc. (OTCQB: SPAIF) (CSE: SPAI) and may include paid advertising.

In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company announced that is has completed the planned enrollment of 50 patients necessary for the interim analysis in its 80-patient confirmatory Phase 3 clinical trial evaluating HyBryte(TM) (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma ( https://ibn.fm/ZeQoN ).

Strawberry Fields REIT (NYSE AMERICAN: STRW) a self-administered REIT focused on healthcare-related properties, said Chairman and CEO Moishe Gubin will present at NobleCon21 on Dec. 3 at 4:30 p.m. Eastern at Florida Atlantic University’s Executive Education Complex. A high-definition webcast will be available on the NobleCon and Channelchek websites and will remain archived for 90 days.

SEGG Media (NASDAQ: SEGG, LTRYW) said its Board terminated CEO, Secretary and President Matthew McGahan and removed him as Chairman, appointing CFO Robert Stubblefield as Interim CEO, Secretary and President and naming Marc Bircham Chairman. McGahan will remain a Director until his term expires at the upcoming annual meeting. The Company said the leadership transition supports its next phase of growth as it scales Sports.com, Concerts.com and Lottery.com, with more than 102 million views across platforms in 2025, and prepares for planned acquisitions. Stubblefield said the focus is on financial stability, disciplined execution and rebuilding shareholder value, while guiding expansion across sports, entertainment and gaming verticals.

This article has been disseminated on behalf of Nicola Mining Inc. and may include paid advertising.

Lelantos Holdings (OTCID: LNTO) said it plans to expand into mineral mining, aggregate mining, and silica production, noting these verticals complement existing operations and support long-term growth, with multiple Letters of Intent expected within seven business days to formalize participation, according to CEO Nathan Puente.

NanoViricides, Inc. (NYSE American: NNVC), a clinical stage global pioneer in broad-spectrum antivirals based on host-mimetic nanomedicine, signed a Master Services Agreement with regulatory consultant Only Orphans Cote, founded by Dr. Timothy Cote. OOC will help develop the Company’s orphan drug strategy for NV-387 and prepare and prosecute related orphan drug designation applications at the US FDA Office of Orphan Products. NanoViricides said NV-387 has shown strong activity in lethal animal models of orthopoxvirus infections, supporting its potential for Smallpox, MPox and Measles orphan designations. Orphan drug status may offer incentives including tax credits, user-fee exemptions and up to seven years of market exclusivity.

NRx Pharmaceuticals (NASDAQ: NRXP) said Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H., will present at NobleCon21 on Dec. 3 at 4:30 p.m. EST, offering an update on the company’s expanded focus in investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions, as well as progress in generating clinical revenue since NobleCon 2024.

This article has been disseminated on behalf of Foremost Clean Energy Ltd. and may include paid advertising.

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

This article has been disseminated on behalf of ESGold Corp. and may include paid advertising.

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

This article has been disseminated on behalf of New Pacific Metals Corp. and may include paid advertising.

HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac-care insights, detailed its strategy following receipt of a Not Substantially Equivalent decision for its 510(k) submission covering its 12-lead ECG Synthesis Software. The Company has been in active discussions with FDA review staff, which have signaled willingness to work toward a constructive resolution. HeartBeam said its VALID-ECG clinical study met endpoints and that remaining FDA concerns may be resolved through revised labeling. To advance the process, the Company plans to pursue multiple parallel paths—including a formal appeal or a 510(k) resubmission—and believes recent interactions indicate a viable path forward under the appeal option, which carries an expected 60-day timeline. HeartBeam will continue providing updates on commercialization and funding plans as regulatory engagement progresses.

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

This article has been disseminated on behalf of Platinum Group Metals Ltd. and may include paid advertising.

As the year comes to a close, copper output in the United States holds firm at 1,077,000 tons. This figure represents an increase of about 1.7% as compared to last year’s output. Experts attribute this slight increase to reduced output from major operations like the Phoenix mine and the Kennecott Copper project.

GAC Group completed construction of China’s first production line for large-format solid-state batteries, putting it on track to begin producing solid state batteries at a globally unprecedented scale. The facility currently operates at limited capacity producing vehicle-grade cells, but the performance targets attached to this technology have attracted international automotive industry attention.

For a long time, the scientific community has known that anything that causes harm to the body usually also harms our brains. Conditions like insulin resistance, obesity and high blood pressure strain the body’s metabolic and vascular systems. With time, this stress accelerates cognitive decline and amplifies Alzheimer’s risk.

A research hub set to open next year at the Johns Hopkins Applied Physics Laboratory aims to bring generative AI into defense wargaming . The GenWar Lab will focus on upgrading traditional tabletop exercises by pairing human participants with large language models such as those behind common AI chatbots.

This article has been disseminated on behalf of ESGold Corp. and may include paid advertising.

This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement.

Renewable energy is proving it can generate real profits while expanding rapidly across the globe. Projects are no longer just experiments or policy-driven pilots, they are delivering steady returns to investors and tangible benefits to local communities. A recent utility scale wind farm in Arkansas shows how clean power can be both commercially viable and scalable, marking a milestone in the sector’s maturation.

A San Francisco homeowner lost an estimated $11 million in crypto after an attacker posing as a delivery worker forced entry during an early morning break-in. The robbery, which occurred in the Mission Dolores area, is among the largest known thefts of digital assets from a private individual in the U.S. this year.

Thai cryptocurrency exchange Bitkub is considering a major move by exploring an initial public offering in Hong Kong. The Bangkok-based exchange, founded in 2018, is one of Thailand’s leading crypto platforms. This decision comes as Thailand’s stock market faces challenges that make a domestic listing less attractive.

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include paid advertising.

Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for Ebola and Marburg-related viruses. An article discussing this reads, “Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C, a capability that could transform global outbreak response readiness. The company’s publication, titled ‘Development of Thermostable Filovirus Vaccines Using Protein Subunit Technology,’ outlines preclinical data showing that the company’s filovirus vaccine antigens, formulated with its proprietary ThermoVax(R) platform, maintained structural integrity and immunogenicity after 12 months of storage at 40°C. The same formulation also outperformed unstabilized comparators that degraded significantly under identical conditions. Most recently, this stability window was increased to at least 2 years (24 months) at 40°C. The publication expands earlier work funded through ongoing U.S. government contracts with BARDA and the National Institute of Allergy and Infectious Diseases.”

Wearable Devices (NASDAQ: WLDS), an AI-based wearable gesture-control technology pioneer, said it entered a warrant inducement agreement with an existing institutional investor for the immediate cash exercise of warrants to purchase 3,322,000 ordinary shares at $1.71 per share, generating approximately $5.68 million in gross proceeds. A.G.P./Alliance Global Partners is serving as exclusive financial advisor. In exchange for the full cash exercise, the Company will issue new unregistered warrants to purchase up to 5,813,500 ordinary shares at $1.86 per share, exercisable upon shareholder approval and expiring five years thereafter. Closing is expected on or about Dec. 1, 2025, subject to customary conditions.

Oregon activists have halted their effort to place a measure on the 2026 ballot that would have legalized marijuana social lounges across the state. The Oregon Cannabis Cafe Coalition confirmed that it has withdrawn the proposal after months of preliminary work, including filing two variations of the measure.

Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include paid advertising.

Nano-X Imaging (NASDAQ: NNOX) entered a securities purchase agreement with a single institutional investor to sell 3,826,530 ordinary shares in a registered direct offering expected to generate approximately $15 million in gross proceeds, with Titan Partners Group, a division of American Capital Partners, serving as sole placement agent. Closing is expected on or about Nov. 25, 2025, and the company plans to use the net proceeds for working capital and general corporate purposes.

Disseminated on behalf of Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) and may include paid advertising.